Introduction
With 1.5% seroprevalence of hepatitis C virus (HCV) infection in the general population, 10% identified cases, and < 2% treatment rate, Slovakia belongs to the countries with low-to-medium prevalence, a low diagnosis rate, and a very low treatment rate, respectively [1] . Introduction of directly acting antivirals (DAA) with a high rate of sustained virological response (SVR), and a very good safety profile, has led to removal of patients with chronic kidney disease (CKD) from the "difficult-to-treat" (DTT) list [2] .
Aim of the study
To determine the prevalence of antibodies to HCV in consecutive outpatients with CKD of any grade.
Material and methods
Prospective cohort study of consecutive incomers to the Nephrology Outpatient Clinic. Inclusion criteria were age > 18 years, informed consent and CKD according to KDIQO [29] . There were no exclusion criterias. Study interval was from November 2015 to March 2016. Recorded variables were gender, age, etiology of CKD, stage of CKD (G1-G5) and anti-HCV antibodies (ELISA -3 rd generation, Cobase 411, Roche). Detection of HCV RNA was not part of the original protocol; after completion of the study, anti-HCV positive patients were contacted and invited with this intent. Funding: This study was supported by a restricted grant of AbbVie Slovakia. The study was approved by the institutional ethics committee, and conducted in agreement with the Declaration of Helsinki.
Results
During the study interval of 5 months, 134 patients with CKD were recruited; female -70 patients (52%), median age -70 years (19.7-91) . Grades of CKD were as follows: G1/2 -52 patients (39%), G3a -34 (25%), G3b -32 (24%), G4 -8 (6%), G5 -8 (6%) (Fig. 1) Table 1) . Eight anti-HCV positive patients were approached after the completion of the protocol with attempt to determine HCV-RNA; 2 of them died before location, and 1 was lost to follow-up. Of the remaining 5 patients, HCV RNA was detected in 1 (20%); this patient was treated with DAA and achieved an SVR.
Discussion
In contrast to CKD 5, data on HCV infection in lower stages are scarce. Although the global impact of HCV infection on the prognosis of patients with CKD has been considered negligible in stage 3, and questionable in stage 4, the consequences can still be devastating -in individual cases due to the association of HCV with the pathogenesis of CKD, and in all after kidney transplantation (RTx) [21] [22] [23] [24] . Before the introduction of DAA, therapy of HCV infection in ESRD and RTx patients had been more than problematic, with only 1% to 5% receiving interferon IFN-based therapy [16, 25] . Nowadays, CKD and renal replacement therapy patients with HCV infection should be indicated (where feasible), and prioritized (where indicated) for the therapy with IFN-and ribavirin-free DAA regimens [2, 26, 27] . DAA have even enabled a safe RTx of HCV positive kidneys to HCV negative recipients [28] . 
HCV -hepatitis C virus; CKD -chronic kidney disease; TIN -tubulointerstitial nephritis, NS -nephrosclerosis; DN -diabetic nephropathy; GN -glomerulonephritis
Studies in Slovak hemodialysis unit (HDUs) from the years 1995, [1997] [1998] [1999] 2006 , and 2015 yielded HCV antibody seroprevalence of 30%, 12.8%, 5%, and 2.5%, respectively (Table 2) [17] . In patients on the waiting list for RTx, the seroprevalence was 2.5% [18] . These results are in accord with decreasing trends from the USA and the European Union [15, 19, 20] . In contrast to these CKD 5 data, those on stages 1-4 are scarce.
To the best of our knowledge, this pilot study is the first of its kind in this region. It has several limitations: i) the setting is a tertiary referral center with a possibility of selection bias; ii) small sample size; iii) lack of more prospective information on the anti-HCV positive cases in terms of viremia, genotype, liver fibrosis, etc. The study is relatively strong in its prospective design, and a strict adherence to the diagnostic criteria of CKD [29] . If the 1.5% figure would be taken as the reference value of anti-HCV antibodies' prevalence in the general population, the 6% prevalence in patients with CKD would be 4-fold increased over the baseline [1] . Unfortunately, our patients were not examined for the presence of HCV RNA immediately after the detection of HCV antibodies, which has led to the loss of 3 of them; of the remaining 5 patients, HCV RNA was detected in only one (20%). This figure is very difficult to interpret, since there are very few data on the anti-HCV:HCV RNA ratio in CKD < 5. In our previous study in hemodialyzed patients, HCV RNA positivity was found in 29 of 38 anti-HCV positive patients (76%) (unpublished data). The most likely explanation for the very low rate of HCV RNA positivity in anti-HCV positive CKD patients is the small number of patients. Since the study was neither designed nor powered to analyze the risk factors for HCV infection, or associations of HCV with the etiology of CKD, one can turn to the results of the meta-analysis by Fabizi et al. [30] . Of note in our cohort are the counterintuitive associations of GN and NS with HCV seronegativity, and the lack of an association of HCV seropositivity with DN; these observations, or lack of them, deserve more attention in the future. The 88% prevalence of CKD < 4 is reassuring as to the main aim of the study (Fig. 1) . As the data from regional HDUs have shown a steady decline in the HCV seroprevalence over the last 20 years, it would be of interest to determine whether these dynamics would by paralleled in a cohort with CKD < 5.
Conclusions
In this pilot study on outpatients with CKD, the prevalence of anti-HCV antibodies was 6%, which is 4 times higher than in the general population. Considering the low HCV infection diagnosis/awareness rates in the region, a cohort with CKD could be scrutinized as the possible target for systematic screening. Preceding such an endeavor, our results should be corroborated in larger-scale, multicentric projects.
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